Disease · MONDO_0018882

vasculitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. vasculitis. Diseases, record MONDO_0018882. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018882

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: vasculitis; Open Targets
Open Targets ID: MONDO_0018882; Open Targets
Other names: Angiitis, Inflammation of blood vessel; Open Targets
Disease Ontology: DOID:865; Disease Ontology
MeSH: D014657; MeSH
NCI Thesaurus: C26912; NCI Thesaurus
Orphanet: ORPHA:52759; Orphanet
Highest stage of its drugs: Approval, for 2 of its 21 drugs, from DailyMed; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Approval	DailyMed	4	3	3	Drugs and targets
MEPOLIZUMAB	CHEMBL2108429	Antibody	Approval	DailyMed	1	0	0	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
IBUPROFEN	CHEMBL521	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CANAKINUMAB	CHEMBL1201834	Antibody	Phase 2	TTD	1	0	0	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1441	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 1	https://conductscience.org/library/genes/1043	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
IL2RA	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3561	Drugs and targets
IL5	Interleukin-5	1	Interleukin-5 inhibitor	Approval	https://conductscience.org/library/genes/3567	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 2	https://conductscience.org/library/genes/3570	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05168475	Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis	Phase 2	22	2025-06-17	Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis, Cryoglobulinemic Vasculitis, IgA Vasculitis, Polyarteritis Nodosa, Cutaneous Polyarteritis Nodosa, Primary Angiitis of Central Nervous System	INFLIXIMAB, RITUXIMAB, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00278512	Hematopoietic Stem Cell Support in Vasculitis	Phase 1	7	2018-08-02	Vasculitis	ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, MESNA, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03760562	The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases		111,804		Hypertension	PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT03692416	The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	Phase 3	70		Vasculitis	IBUPROFEN, METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT03482479	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Phase 2	60		Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis	NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00753103	Anti-Cytokine Therapy for Vasculitis	Phase 2	37		Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00293072	Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis	Phase 2	20		Systemic Lupus Erythematosus, ANCA Associated Vasculitis	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00006055	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases	Not applicable	10		Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis	CYCLOPHOSPHAMIDE, CYCLOSPORINE, FILGRASTIM, METHYLPREDNISOLONE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00574652	Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients	Phase 1/2	10		Cryoglobulinemia Vasculitis	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32392512	DERIVED	1	PubMed
22129253	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018882

GET https://conductscience.org/api/diseases/v1/MONDO_0018882/drugs?page=2

API reference For AI assistants